Interstitial Lung Disease Growth Forecast 2025-2034: Trends, Opportunities, and Key Insights You Need to Know
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Predicted CAGR for the Interstitial Lung Disease Market Over the Forecast Period of 2025 to 2034?
The market size of interstitial lung disease has seen a robust growth recently. It is projected to expand from $1.97 billion in 2024 to $2.11 billion in 2025, with a compound annual growth rate (CAGR) of 7.2%. Factors contributing to the growth in the past have been increased awareness and advancements in diagnostics, therapies modulating the immune system, respiratory rehabilitation programs, and the introduction of multidisciplinary care teams.
In the coming years, the market size for interstitial lung disease is projected to significantly expand, with expectations to reach a worth of $2.85 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth anticipated within the projected timeline is mainly due to factors such as precision medicine, the introduction of new drugs, regenerative medicine, along with telehealth and remote monitoring. Key trends that will mark this period of growth include advancements in imaging technology, the use of artificial intelligence in imaging, differentiation of fibrosis subtypes, and the provision of supportive care services.
How Are the key drivers Contributing to the Expansion of the interstitial lung disease Market?
The surge in allergic conditions is anticipated to fuel the expansion of the interstitial lung disease market. Allergies are characterized by the immune system’s exaggerated response to an allergen, often an innocuous substance. One particular form of interstitial lung disease (ILD) could occur as a result of allergic reactions, specifically hypersensitivity pneumonitis, which causes allergic responses in the body. Reportedly in November 2023, the National Asthma Council, an Australian non-profit organization dedicated to improving asthma care and management, disclosed 467 asthma-related fatalities in 2022, with 299 females and 168 males. This marked an increase from the 355 deaths in 2021. Consequently, the upswing in allergic diseases is propelling the skin health foods market’s growth, reinforcing the role allergic conditions play in driving the interstitial lung disease market’s expansion. An uptick in autoimmune disorders is projected to bolster the interstitial lung disease market’s progress. Autoimmune disorders are health issues when the immune system mistakenly attacks the body’s normal tissues and cells. The increasing occurrence of these conditions promotes demand for healthcare services related to ILD, enhances research and development, and cultivates advancements in treatment and patient care. As of September 2023, the Institute for Health Metrics and Evaluation, a US-based global health research institute, predicts that rheumatoid arthritis cases worldwide are set to rise to 31.7 million by 2050, marking a considerable surge. Consequently, an increase in autoimmune disorders is driving the growth of the interstitial lung disease market.
Get Your Free Sample of the Global Interstitial Lung Disease Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13019&type=smp
Who Are the Top Companies Driving Innovation and Growth in the Interstitial Lung Disease Market?
Major companies operating in the interstitial lung disease market are:
• Roche Laboratories Inc._x000D_
• Merck & Co. Inc._x000D_
• Bayer AG_x000D_
• Novartis Pharmaceuticals Corporation_x000D_
• The Bristol-Myers Squibb Company_x000D_
What Key Trends Are Currently Impacting the Interstitial Lung Disease Market’s Development?
In the interstitial lung disease market, dominant companies are riding the trend of launching products such as innovative treatments for several interstitial lung illnesses, including idiopathic pulmonary fibrosis (IPF). IPF is a long-term lung ailment characterized by lung tissue scarring, resulting in breathing problems and a decline in oxygen transfer. For example, C.H. Boehringer Sohn AG & Co. KG, a biopharmaceutical firm based in Germany, gained FDA approval in February 2024 for BI 1015550 Therapy for treating Idiopathic Pulmonary Fibrosis. BI 1015550 is an experimental oral treatment that suppresses phosphodiesterase 4B (PDE4B), exerting antifibrotic and anti-inflammatory effects to retard the deterioration of lung function in IPF cases.
Get Instant Access to the Global Interstitial Lung Disease Market Report with Swift Delivery!
https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report
Which Segments Play a Crucial Role in the Expansion of the Interstitial Lung Disease Market?
The interstitial lung disease market covered in this report is segmented –
1) By Drug Type: Oral Corticosteroids, Immune Suppressing, Anti-Fibrotic Medication, Other Drugs
2) By Disease Type: Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonitis, Hypersensitivity Pneumonitis, Cryptogenic Organizing Pneumonia (COP), Sarcoidosis, Acute Interstitial Pneumonitis
3) By Application: Adults, Children
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Oral Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone
2) By Immune Suppressing: Azathioprine, Methotrexate, Mycophenolate Mofetil
3) By Anti-Fibrotic Medication: Pirfenidone, Nintedanib
4) By Other Drugs: Antioxidants, Anticoagulants, Other Novel Therapies
Which Geographical Regions Are Pioneering Growth in the Interstitial Lung Disease Market?
North America was the largest region in the interstitial lung disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interstitial lung disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Key Characteristics That Define the Interstitial Lung Disease Market?
Interstitial lung disease (ILD) refers to lung conditions that affect the interstitium, the tissue and the area surrounding the alveoli in the lungs. The interstitium is essential for maintaining the structural integrity and function of the lungs, as it supports gas exchange between the lungs and the bloodstream.
Browse Through More Similar Reports By The Business Research Company:
Respiratory Disease Testing Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report
Anesthesia And Respiratory Devices Global Market Report 2024
Respiratory Protection Equipment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
